Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62018TN0321

    Case T-321/18: Action brought on 18 May 2018 — Serenity Pharmaceuticals v EUIPO — Gebro Holding (NOCUVANT)

    OJ C 240, 9.7.2018, p. 61–61 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    201806220751970242018/C 240/703212018TC24020180709EN01ENINFO_JUDICIAL20180518616111

    Case T-321/18: Action brought on 18 May 2018 — Serenity Pharmaceuticals v EUIPO — Gebro Holding (NOCUVANT)

    Top

    C2402018EN6110120180518EN0070611611

    Action brought on 18 May 2018 — Serenity Pharmaceuticals v EUIPO — Gebro Holding (NOCUVANT)

    (Case T-321/18)

    2018/C 240/70Language in which the application was lodged: English

    Parties

    Applicant: Serenity Pharmaceuticals LLC (Milford, Pennsylvania, United States) (represented by: J. Day, Solicitor)

    Defendant: European Union Intellectual Property Office (EUIPO)

    Other party to the proceedings before the Board of Appeal: Gebro Holding GmbH (Fieberbrunn, Austria)

    Details of the proceedings before EUIPO

    Applicant of the trade mark at issue: Applicant

    Trade mark at issue: EU word mark NOCUVANT — Application for registration No 13 053 434

    Procedure before EUIPO: Opposition proceedings

    Contested decision: Decision of the Second Board of Appeal of EUIPO of 8 March 2018 in Case R 584/2017-2

    Form of order sought

    The applicant claims that the Court should:

    annul the contested decision;

    annul the decision of the Opposition Division of 27 January 2018 in Opposition No. B 002437922;

    order EUIPO and Gebro Holdings GmbH to bear their own costs and pay those of the Applicant.

    Pleas in law

    Infringement of Article 47(2) of Regulation No 2017/1001;

    Infringement of Article 8(1)(b) of Regulation No 2017/1001.

    Top